Back to results

MB-CART19.1 in Patients With R/R ALL

Primary Purpose

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory

Status

Unknown status

Phase

Phase 2

Locations

Study Type

Interventional

Intervention

MB-CART19.1

About this trial

This is an interventional treatment trial for Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory focused on measuring B cell Acute Lymphoblastic Leukemia, relapsed or refractory, CD-19 Positive

Eligibility Criteria

2 Months - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age ≤18 years (if deemed fit by treating investigator)
CD19 expression must be detected on the malignant cells by flow cytometry.
Patients with relapsed disease with >5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for allogeneic stem cell transplant (alloSCT)
Patients have refractory disease activity precluding alloSCT at this time, or patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
Patients with combined extramedullary ALL are eligible if extramedullary disease has been successfully cleared by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy). This includes patients with combined CNS-2 (<5 WBC/µl CSF, with blasts on cytospin) or CNS-3 (5WBC/µl CSF, with blasts on cytospin) disease and patients with combined testicular relapse.
Patients and/or parents must give their written informed consent/assent.

Exclusion Criteria:

Rapidly progressive disease that in the estimation of live less than 12 weeks
Isolated extramedullary relapse (CNS and/or testicular) in ALL
Current autoimmune disease, or history of autoimmune disease with potential CNS involvement
Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis)
History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years.
Pulmonary function: Patients with pre-existing severe lung disease (FEV1 or FVC < 65%) or an oxygen requirement of >28% O2 supplementation or active pulmonary infiltrates on chest X-ray at the time scheduled for T cell infusion
Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography
Renal function: Creatinine clearance <50 mL/min/1.73 m2

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CRA treatment

Arm Description

The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg. A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells.

Outcomes

Primary Outcome Measures

Overall response rate

ORR in ALL patients is defined as the rate of complete remission (CR, CRh) on day 28

Secondary Outcome Measures

Overall incidence and severity of adverse events.

Overall incidence and severity of adverse events will measure in this trial. Including: 1,Risks related to targeting of CD19+ normal B-cells; 2,Allergic reactions to CAR T cell infusion; 3, Cytokine release syndrome (CRS); 4, neurological toxicities; 5,Risks related to transfer of donor T cells after previous alloSCT; 6, Risks related to lentiviral gene transfer into human cells.

Rate of ALL patients achieving MRD negative CR

The rate of ALL patients achieving MRD negative CR in D28; 3,6,12months.

Relapse rate and time to relapse

Overall rate of relapse and the time to relapse from CART cell transfused.

Full Information

NCT ID

NCT03321123

First Posted

September 20, 2017

Last Updated

October 22, 2017

Sponsor

Shanghai Children's Medical Center

Collaborators

Miltenyi Biomedicine GmbH

1. Study Identification

Unique Protocol Identification Number

NCT03321123

Brief Title

MB-CART19.1 in Patients With R/R ALL

Official Title

Adoptive Therapy With MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia

Study Type

Interventional

2. Study Status

Record Verification Date

October 2017

Overall Recruitment Status

Unknown status

Study Start Date

December 1, 2017 (Anticipated)

Primary Completion Date

July 1, 2019 (Anticipated)

Study Completion Date

December 31, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Shanghai Children's Medical Center

Collaborators

Miltenyi Biomedicine GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

5. Study Description

Brief Summary

Precursor-B acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Despite major advances in ALL therapy, 20% of children and 40-50% of adults fail state-of-the art first-line treatment. But there is a strong need for alternative treatments to cure chemotherapy-refractory and relapsed B cell malignancies in pediatric patients. Relapsed and refractory B cell malignancies remain a therapeutic challenge, as these diseases are characterized by adverse survival. These cancers share a cell origin from the B-cell lineage and consequent surface expression of B-lineage markers such as CD19 and CD22. Chimeric antigen receptor (CAR) engineered T cell therapy has recently emerged as a new modality to target B cell malignancies. CARs couple a single-chain Fv (scFv) domain directed against a B-lineage-specific antigen to T-cell activating intracellular signaling domains. CAR gene-modified T cell interaction with target cells occurs in a HLA-independent fashion, so that a single vector can be used to treat all patients with cancers that express the target antigen. Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In the proposed phase II study, the investigator will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.

Detailed Description

This is an open-label, non-randomized phase II paediatric study. In this study, eligible patients will receive autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1) at a doesage of 2x10e6 ~2x10e7 CAR-transduced T cells/kg. Upon enrollment, leukapheresis will be performed for MB-CART19.1 generation. Patients with high disease burden at screening (e.g. ALL with M3 marrow and 10.000/L blasts in peripheral blood) may receive bridging chemotherapy after leukapheresis, to avoid critical tumor lysis syndrome and cytokine release syndrome (CRS) by subsequent lymphodepleting chemotherapy and CAR transfer. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells. Patients will receive freshly prepared MB-CART19.1 on day 0, corresponding to day 12 (48 hours) of manufacturing, at a dose of 2x10e6 ~2x10e7/kg MB-CART19.1 T cells as defined in the study design section. The appropriate volume for the target cell dose will be drawn up and given as an IV injection over 30 minutes through a large vein peripherally or centrally. The primary objectives are: To assess the safety and tolerability of MB-CART19.1. To evaluate the biological activity of adoptive transfer of autologous MB-CART19.1 in patients with R/R CD19-positive B cell lymphoblastic leukemia. The primary endpoint is Overall response rate (ORR):ORR in ALL patients is defined as the rate of complete remission (CR, CRh) on day 28.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory

Keywords

B cell Acute Lymphoblastic Leukemia, relapsed or refractory, CD-19 Positive

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

CRA treatment

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

MB-CART19.1

Other Intervention Name(s)

Miltenyi CD-19 CAT-T cell

Intervention Description

Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.

Primary Outcome Measure Information:

Title

Overall response rate

Description

ORR in ALL patients is defined as the rate of complete remission (CR, CRh) on day 28

Time Frame

1 Month

Secondary Outcome Measure Information:

Title

Overall incidence and severity of adverse events.

Description

Time Frame

1 Months

Title

Rate of ALL patients achieving MRD negative CR

Description

The rate of ALL patients achieving MRD negative CR in D28; 3,6,12months.

Time Frame

12 Months

Title

Relapse rate and time to relapse

Description

Overall rate of relapse and the time to relapse from CART cell transfused.

Time Frame

12 Months

Other Pre-specified Outcome Measures:

Title

Disease-free and overall survival at 1 year after adoptive immunotherapy with MB-CART19.1 in patients not receiving alloSCT

Description

CART treatment is an adoptive immunotherapy, and the CART cells will disaper after infusion. Then the patient relapsed. Allo-SCT can rebuild a new immune system to detec and destory cancer cell.

Time Frame

12 Months

Title

Level of circulating CAR T cells

Description

CART treatment is an adoptive immunotherapy, and the CART cells will disaper after infusion. The investigator need to detec the circulating CAR-T cell after infusion regularly.

Time Frame

12 Months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

2 Months

Maximum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age ≤18 years (if deemed fit by treating investigator) CD19 expression must be detected on the malignant cells by flow cytometry. Patients with relapsed disease with >5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for allogeneic stem cell transplant (alloSCT) Patients have refractory disease activity precluding alloSCT at this time, or patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment. Patients with combined extramedullary ALL are eligible if extramedullary disease has been successfully cleared by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy). This includes patients with combined CNS-2 (<5 WBC/µl CSF, with blasts on cytospin) or CNS-3 (5WBC/µl CSF, with blasts on cytospin) disease and patients with combined testicular relapse. Patients and/or parents must give their written informed consent/assent. Exclusion Criteria: Rapidly progressive disease that in the estimation of live less than 12 weeks Isolated extramedullary relapse (CNS and/or testicular) in ALL Current autoimmune disease, or history of autoimmune disease with potential CNS involvement Active clinically significant CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis) History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years. Pulmonary function: Patients with pre-existing severe lung disease (FEV1 or FVC < 65%) or an oxygen requirement of >28% O2 supplementation or active pulmonary infiltrates on chest X-ray at the time scheduled for T cell infusion Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography Renal function: Creatinine clearance <50 mL/min/1.73 m2

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Jing Chen, MD, PhD

Phone

86 18930830632

chenjing@scmc.com.cn

First Name & Middle Initial & Last Name or Official Title & Degree

Benshang Li, MD, PhD

Phone

86 18101893712

libenshang@scmc.com.cn

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Jing Chen, MD,PhD

Organizational Affiliation

Shanghai Children Medicine Center

Official's Role

Principal Investigator

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Learn more about this trial

MB-CART19.1 in Patients With R/R ALL

We'll reach out to this number within 24 hrs